Neurogene Inc. (NGNE)
Neurogene Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $28.31, down 9.41% on the session, giving a market capitalisation of $447.4M. On trailing twelve-month figures it carries a trailing P/E of -5.14, a net margin of 0.0%. Its beta of 1.96 implies it has historically moved more than the broad market.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Neurogene Inc. is most often compared with the following Healthcare names: